These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6285946)

  • 1. Biliary excretion of amoxycillin and ceftriaxone after intravenous administration in man.
    Maudgal DP; Maxwell JD; Lees LJ; Wild RN
    Br J Clin Pharmacol; 1982 Aug; 14(2):213-7. PubMed ID: 6285946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftriaxone: renal and biliary excretion and effect on the colon microflora.
    Arvidsson A; Alván G; Angelin B; Borgå O; Nord CE
    J Antimicrob Chemother; 1982 Sep; 10(3):207-15. PubMed ID: 6292158
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal excretion of intravenously infused amoxycillin and ampicillin.
    Sjövall J; Westerlund D; Alván G
    Br J Clin Pharmacol; 1985 Feb; 19(2):191-201. PubMed ID: 3986077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biliary excretion of ceftizoxime in humans.
    Brogard JM; Arnaud JP; Timmler R
    Chemotherapy; 1984; 30(4):221-6. PubMed ID: 6086245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difference in blister fluid penetration after single and multiple doses of ceftriaxone.
    LeBel M; Grégoire S; Caron M; Bergeron MG
    Antimicrob Agents Chemother; 1985 Jul; 28(1):123-7. PubMed ID: 4037771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys.
    Matsui H; Komiya M; Ikeda C; Tachibana A
    Antimicrob Agents Chemother; 1984 Aug; 26(2):204-7. PubMed ID: 6091536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection.
    Scully BE; Fu KP; Neu HC
    Am J Med; 1984 Oct; 77(4C):112-6. PubMed ID: 6093511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ceftriaxone in humans.
    Patel IH; Chen S; Parsonnet M; Hackman MR; Brooks MA; Konikoff J; Kaplan SA
    Antimicrob Agents Chemother; 1981 Nov; 20(5):634-41. PubMed ID: 6275779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of parenteral amoxycillin, biliary excretion and effect of renal failure.
    Chelvan P; Hamilton-Miller JM; Brumfitt W
    J Antimicrob Chemother; 1979 Mar; 5(2):232-3. PubMed ID: 429253
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of ceftriaxone and its relation to concentrations in extravascular compartments. Comparison with cefotaxime.
    Regamey C
    Chemotherapy; 1985; 31(2):85-94. PubMed ID: 3987394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amoxycillin levels in human serum, bile, gallbladder, lung, and liver tissue.
    Kiss IJ; Faragó E; Schnitzler J; Várhelyi I
    Int J Clin Pharmacol Ther Toxicol; 1981 Feb; 19(2):69-74. PubMed ID: 7216553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and quantitative characterization of cefotiam excretion after intravenous administration to patients after cholecystectomy.
    Terziivanov D; Gerova Z; Vlahov V; Merdzhanov A; Damjanov D
    Eur J Clin Pharmacol; 1986; 30(4):439-44. PubMed ID: 3462003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High biliary elimination of ceftriaxone in man.
    Brogard JM; Blickle JF; Jehl F; Arnaud JP; Paris-Bockel D; Monteil H
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):167-72. PubMed ID: 3403093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile of ceftriaxone in man.
    Patel IH; Kaplan SA
    Am J Med; 1984 Oct; 77(4C):17-25. PubMed ID: 6093513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biliary excretion of cefotaxime and desacetylcefotaxime].
    Jehl F; Peter JD; Picard A; Dupeyron JP; Marescaux J; Sibilly A; Monteil H
    Rev Med Interne; 1987; 8(5):487-92. PubMed ID: 3445030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Concentrations of cefmenoxime and cefotiam in the bile and gallbladder tissue following intravenous administration in patients with biliary tract diseases].
    Shoda Y; Matsuyama S; Takarada A; Arai M; Nagashima K; Nakano G; Nakamura T; Kamisaka K; Matsuzawa T; Yoshino T
    Jpn J Antibiot; 1986 May; 39(5):1259-72. PubMed ID: 3463776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.
    McNamara PJ; Stoeckel K; Ziegler WH
    Eur J Clin Pharmacol; 1982; 22(1):71-5. PubMed ID: 6284519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Laboratory and clinical investigations of cefotiam in surgical biliary tract infections].
    Oikawa M; Watanabe I
    Jpn J Antibiot; 1982 May; 35(5):1153-62. PubMed ID: 6290699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute bioavailability of ceftriaxone after intramuscular administration to healthy volunteers.
    Delsignore R; Baroni CM; Crotti G; Mineo F; Butturini U; Ascalone V; Cisternino M
    Chemotherapy; 1983; 29(3):157-62. PubMed ID: 6307601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy.
    Guggenbichler JP; Allerberger FJ; Dierich M
    Padiatr Padol; 1986; 21(4):335-42. PubMed ID: 3562044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.